The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...

The successful financings come amid a more than two-year stretch when the sector has struggled to attract fresh capital with ...

U.S. Rep. April McClain Delaney visited Kite, a biopharmaceutical company that uses cell therapy to treat cancer, in Urbana on Thursday morning, one of several locations across her district she ...

Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...